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Glycated hemoglobin (HbA1c) ≥6.5% has been recommended as an alternative diagnostic 
criterion for diabetes. However, its concordance with fasting plasma glucose level (FPG) in 
acutely unwell patients such as during ST-elevation myocardial infarction (STEMI) is 
unknown. Moreover, its prognostic implication is unclear. This study demonstrated that the 
diagnostic concordance between HbA1c and FPG in STEMI patients was poor. Furthermore, 



















Background: World Health Organization and American Diabetes Association recommend 
HbA1c ≥6.5% as diagnostic for diabetes. However, concordance between fasting plasma 
glucose (FPG) and HbA1c in acutely unwell patients is unknown. Furthermore, prognostic 
value of HbA1c for left ventricular (LV) dysfunction is unclear. This study aimed to evaluate 
the concordance between HbA1c and FPG in consecutive acute ST-elevation myocardial 
infarction (STEMI) patients, and compare their prognostic value in predicting LV 
dysfunction and elevated filling pressures on echocardiography. 
Methods: A total of 142 first STEMI patients were prospectively recruited. LV diastolic 
function was defined as mean septal and lateral early diastolic velocities (average e’); filling 
pressure was the ratio of transmitral E velocity to average e’ (average E/e’).  
Results: Mean FPG and HbA1c were 7.7±2.8mmol/L and 6.5±1.6% respectively. Of 109 
patients without prior diabetes, HbA1c identified an additional 18 patients (16.5%) as 
diabetic, and the concordance with FPG was poor. Between diabetic and non-diabetic 
patients, there were no differences in LV end-diastolic volume (116±37 vs. 118±43mL, 
p=0.78), end-systolic volume (69±33 vs. 68±35mL, p=0.93), ejection fraction (42±12 vs. 
44±11%, p=0.49). On multivariable analyses, average e’ was independently associated with 
HbA1c (β=-0.161, p=0.045), but not FPG (p=0.82). Similarly, average E/e’ was 
independently associated with HbA1c (β=0.168, p=0.04), but not FPG (p=0.32). ROC 
analysis showed HbA1c cut-off of 6.4% (AUC=0.68, p=0.002) was associated with an 
elevated LV filling pressure.  
Conclusion: Only HbA1c was independently associated with impaired LV diastolic function 
and increased filling pressures after STEMI. 


















 Diabetes mellitus is a major risk factor for myocardial infarction and a predictor of 
adverse outcomes.1, 2 In patients presenting with acute myocardial infarction, the association 
between high blood sugar level (FPG) on admission and adverse outcomes have been well 
described in various studies.1, 3, 4 However, non-diabetic patients can often develop stress 
hyperglycemia in the setting of an acute illness, complicating the diagnosis of diabetes. 
Although stress hyperglycemia in non-diabetic patients is associated with worse outcomes, 
previous studies included both fasting and post-prandial admission plasma glucose 
concentrations. Therefore, it is unclear if hyperglycemia is a marker of a sicker patient or 
causative for worse outcome. 
 Recently, the World Health Organization and American Diabetes Association 
endorsed the use of glycated hemoglobin (HbA1c) for the diagnosis of diabetes.5, 6 Although 
the evaluation of HbA1c is more convenient compared to FPG in the setting of acute illness, 
no studies to date have used it or compared it to FPG in patients with acute ST-elevation 
myocardial infarction (STEMI). Furthermore, only 1 study to date has evaluated the 
association between HbA1c and left ventricular (LV) dysfunction on echocardiography 2 
months after STEMI 7, and none have compared the prognostic values of HbA1c versus FPG 
for LV dysfunction acutely after STEMI. Therefore, the aims of the present study were to 
evaluate the concordance between HbA1c and FPG in consecutive acute STEMI patients, and 
compare their prognostic value in predicting the extent of LV dysfunction and elevated filling 
pressures on echocardiography. 
 
METHODS 

















 A total of 142 consecutive patients who presented with first STEMI were 
prospectively recruited. STEMI was defined as cardiac chest pain with ECG changes 
consistent with acute myocardial infarction (ST elevation > 2mm in the precordial leads and 
> 1mm in the limb leads) as per current recommendations.8 Exclusion criteria included 
patients with previous myocardial infarction, in-hospital death before echocardiogram could 
be performed, cardiogenic shock requiring inotropic support in intensive care unit, admission 
with acute coronary syndrome/non-STEMI, previously known LV systolic dysfunction, 
greater than moderate valvular heart disease, and known conditions that may affect HbA1c 
measurements (including hemoglobinopathies, chronic liver disease, chronic renal failure, 
previous splenectomy).  
On admission, all patients had baseline clinical variables recorded that included 
cardiac risk factors such as previously diagnosed diabetes, FPG, HbA1c, serial cardiac 
troponin I (cTnI), creatinine kinase MB isoform (CK-MB), glomerular filtration rates (GFR) 
calculated by the Modification of Diet in Renal Disease formula.9 All patients underwent a 
transthoracic echocardiography, invasive coronary angiography, and revascularization if 
required prior to hospital discharge. The median time difference between admission and 
echocardiography was 1 day (25th and 75th percentile 1 and 2 days respectively). 
 In patients not previously known to be diabetic, respective new diagnosis of diabetes 
by HbA1c (≥ 6.5%) and FPG (≥ 7.0 mmol/L) were based on recommendations by the World 
Health Organization and American Diabetes Association 5, 6, and their concordance in 
diagnosis was determined. Patients with abnormal results on initial testing were confirmed 
with repeat testing as recommended by current guidelines.5, 6 To compare the prognostic 
value of HbA1c versus FPG after STEMI, their independent predictive value for LV diastolic 
function (average e’) and filling pressures (average E/e’) were determined. 

















HbA1c measurements were performed using high performance liquid chromatography 
cation-exchange analyzers by Bio-Rad D-10TM Hemoglobin Testing System (Bio-Rad 
Laboratories, Inc., Hercules, CA). This assay is National Glycohemoglobin Standardization 
Program (NGSP) and International Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) certified, and standardized to the Diabetes Control and Complications Trial 
(DCCT) assay. The overall precision of the assay expressed as percentage of coefficient of 
variation for normal and diabetic patients were 1.16% and 1.22% respectively. FPG readings 
were derived from plasma. HbA1c and FPG were measured after an overnight fast on the first 
morning after admission.  
Echocardiography 
Transthoracic echocardiography was performed with the subjects at rest using 
commercially available ultrasound systems (Vivid 7 and E9, GE-Vingmed, Horten, Norway; 
iE33, Philips Medical System, Andover, MA, USA). All images were digitally stored on hard 
disks for offline analysis. A complete 2D, color, pulsed and continuous-wave Doppler 
echocardiogram was performed according to standard techniques.10, 11  LV end-diastolic 
volume (EDV) and end-systolic volume (ESV) were calculated using Simpson’s biplane 
method of discs, and LV ejection fraction (EF) was calculated and expressed as a percentage. 
LV mass was calculated from the formula as recommended by the American Society of 
Echocardiography.12 
Mitral inflow velocities were recorded using conventional pulsed-wave Doppler 
echocardiography in the apical 4-chamber view using a 2 mm sample volume. Transmitral 
early (E wave) and late (A wave) diastolic velocities as well as deceleration time were 
recorded at the mitral leaflet tips. 
Pulsed-wave tissue Doppler velocities were recorded at the septal and lateral mitral 

















lateral early diastolic velocities were calculated (average e’) at end-expiration as 
recommended.13 Similarly, LV filling pressure (average E/e’) was calculated as the ratio of 
transmitral E wave velocity to average e’. 
In 15 randomly selected patients, the intra- and interobserver measurement 
variabilities for average e’ expressed as absolute differences were 0.25 ± 0.24 cm/s and 0.53 
± 0.63 cm/s respectively (intraclass correlations 0.99 and 0.97 respectively). Similarly, the 
intra- and interobserver measurement variabilities for average E/e’ were 0.30 ± 0.18 and 0.73 
± 0.38 respectively (intraclass correlations 0.99 and 0.98 respectively). 
 
Statistical analysis 
Continuous variables were presented as mean ± 1 SD unless otherwise stated, and 
categorical variables were presented as frequencies and percentages. Comparisons between 
diabetic and non-diabetic patients were performed using independent t-test and Mann 
Whitney U test for continuous variables of Gaussian and non-Gaussian distribution 
respectively, Chi square test for categorical variables when no cells have an expected count 
of < 5, and Fisher’s exact test for categorical variables when at least 1 cell has an expected 
count of < 5. Kappa was used to determine the concordance between newly diagnosed 
diabetes by HbA1c versus FPG in patients not previously known to be diabetic on clinical 
history. Pearson correlation was employed to examine the linear association between 2 
continuous variables. Multiple linear regression analyses were then performed to identify 
independent clinical and echocardiographic determinants of LV diastolic function (average 
e’) and filling pressure (average E/e’) for patients after STEMI. All univariable predictors 
with p < 0.10 were simultaneously entered into the multiple linear regression models. To 
avoid multicolinearity between the univariate predictors, a tolerance of < 0.5 (which 

















FPG and HbA1c, they were entered separately in 2 different models. Validity of the multiple 
linear regression models were established by confirming the residuals to be normally 
distributed. ROC curve was used to determine the optimal HbA1c cut-off value associated 
with an elevated LV filling pressure (average E/e’ ≥ 13). A 2-tailed p value of < 0.05 was 
considered significant. All statistical analyses were performed using IBM SPSS Statistics for 
Windows, version 22.0 (Armonk, NY). 
 The study was approved by the Institutional Review Board.  
 
RESULTS 
 A total of 142 first STEMI patients were recruited. Table 1 outlines the baseline 
characteristics for the entire study population. The mean age was 61.8 ± 12.1 years, 106 
(74.6%) male. On admission, the mean FPG and HbA1c were 7.7 ± 2.8 mmol/L and 6.5 ± 
1.6% respectively. FPG was significantly correlated with HbA1c (r = 0.79, p < 0.001). A total 
of 33 (23.2%) patients were previously known to be diabetic on admission based on history. 
These patients had significantly higher FPG (11.2 ± 3.4 vs. 6.7 ± 1.5 mmol/L, p < 0.001) and 
HbA1c (8.4 ± 2.1 vs. 6.0 ± 0.9%, p < 0.001). There were no differences in the proportion of 
pre-existing diabetic versus non-diabetic patients who underwent coronary angioplasty (p = 
0.50) or coronary artery bypass surgery (p = 0.39). 
New diagnosis of diabetes by HbA1c versus FPG 
 Of the 109 patients not previously known to be diabetic, HbA1c ≥ 6.5% identified an 
additional 18 patients (16.5%) as diabetic (Figure 1). Of these 18 patients, 67% had FPG ≥ 
7.0 mmol/L on admission. In contrast, of the 109 patients not previously known to be 
diabetic, 31 patients had FPG ≥ 7.0 mmol/L on admission, but only 29% of them had HbA1c 
≥ 6.5%. The concordance between newly diagnosed diabetes by FPG versus HbA1c was poor 

















 Table 1 outlines the comparisons between patients identified as diabetic based on 
clinical history and HbA1c versus non-diabetic patients. Patients identified as diabetic by 
clinical history and HbA1c had significantly higher average E/e’ (12.5 ± 4.7 vs. 10.0 ± 3.3, p 
= 0.001) and a trend towards lower average e’ (6.6 ± 2.1 vs. 7.4 ± 2.7 cm/s, p = 0.057). There 
were no significant differences in LVEDV (116 ± 37 vs. 118 ± 43 mL, p = 0.78), LVESV (69 
± 33 vs. 68 ± 35 mL, p = 0.93) and LVEF (42 ± 12 vs. 44 ± 11%, p = 0.49). 
 In contrast, patients labeled as diabetic by clinical history and FPG had no differences 
in average E/e’ (11.4 ± 4.1 vs. 10.5 ± 3.6, p = 0.22), average e’ (7.0 ± 3.1 vs. 7.3 ± 2.0 cm/s, p 
= 0.56), LVEDV (115 ± 33 vs. 119 ± 47 mL, p = 0.64), LVESV (69 ± 29 vs. 69 ± 38 mL, p > 
0.99) or LVEF (42 ± 12 vs. 44 ± 12%, p = 0.27). 
Determinants of LV diastolic function and filling pressures 
 Table 2 outlines all the significant univariable and multivariable determinants of LV 
diastolic function by average e’. On univariable analyses, LV diastolic function was 
correlated with age (r = -0.239, p = 0.005) and LVEF (r = 0.272, p = 0.001). There was a 
trend towards more impaired average e’ with higher HbA1c (r = -0.161, p = 0.059) and 
higher FPG (r = -0.161, p = 0.20). There was no significant difference in average e’ between 
men and women (7.3 ± 2.7 vs. 6.5 ± 2.0 cm/s, p = 0.12). To identify the independent 
determinants of LV diastolic function after STEMI by average e’, all univariable predictors 
with p < 0.10 (age, LVEF, HbA1c) were simultaneously entered into the multiple linear 
regression model. Table 2 shows that HbA1c was an independent determinant of LV diastolic 
function after STEMI (standardized β = -0.161, p = 0.045). In contrast, when FPG was forced 
into the model in place of HbA1c, it was not an independent determinant of LV diastolic 
function. 
On univariable analyses, LV filling pressure by average E/e’ was correlated with age 

















was a trend towards higher average E/e’ with FPG (r = 0.162, p = 0.078). Men also had 
significantly lower average E/e’ compared to women (10.2 ± 3.5 vs. 13.0 ± 4.9, p = 0.004). 
On multivariable analysis, HbA1c (standardized β = 0.168, p = 0.04) was an independent 
determinant of LV filling pressure after STEMI (Table 2). Similarly, when FPG on admission 
was entered into the model in place of HbA1c, it was not an independent determinant of LV 
filling pressure after STEMI. 
 ROC analysis showed that an optimal HbA1c cut-off of 6.4% (AUC = 0.68, p = 
0.002) was associated with an elevated LV filling pressure (average E/e’ ≥ 13) (Figure 2). 
 
DISCUSSION 
 The present study is first to utilize HbA1c to diagnose diabetes in STEMI patients. 
The authors demonstrated that although there was good correlation between FPG and HbA1c, 
their concordance in acute STEMI patients was poor due to the epiphenomenon of stress 
hyperglycemia. Compared to FPG, only HbA1c was an independent determinant of diastolic 
dysfunction and elevated filling pressures after acute STEMI, and a cut-off value of 6.4% was 
associated with elevated filling pressures on echocardiography. 
Diagnosing diabetes during acute illness 
Traditionally, the diagnostic criteria for diabetes include FPG ≥ 7.0 mmol/L, 2 hour 
FPG ≥ 11.1 mmol/L after an oral glucose tolerance test, or random plasma glucose 
concentration of ≥ 11.1 mmol/L with symptoms of hyperglycemia. However, both the World 
Health Organization and American Diabetes Association recently also recommended HbA1c 
≥ 6.5% as diagnostic of diabetes.5, 6 Compared to the “traditional” diagnostic criteria for 
diabetes, HbA1c has the advantage of avoiding the need for patient fasting, special dietary 
preparations for an oral glucose tolerance test, and the usual day-to-day variability in random  

















The various cut-off values for HbA1c, FPG and 2 hour plasma glucose levels post 
oral glucose tolerance test were based on threshold levels associated with an increased 
retinopathy prevalence in epidemiological studies.5, 6 However, diagnostic tests that utilize 
blood glucose readings are inaccurate in acutely unwell patients due to the epiphenomenon of 
stress hyperglycemia whereby FPG becomes elevated in the absence of underlying diabetes. 
Therefore, if FPG was used as a diagnostic criterion, the overall incidence of diabetes in this 
study would have been significantly overestimated at 45.0%. 
In contrast, epidemiological studies demonstrated that the incidence of diabetes in 
patients with acute myocardial infarction was significantly lower at 20-30%.14-17 In the latest 
Worcester Heart Attack Study, a population-based investigation on 478,000 residents in the 
greater Worchester region hospitalized with acute myocardial infarction, the incidence of 
diabetes was only 26.6%.16 However, history of diabetes was based on medical records and 
the authors were unlikely to have utilize HbA1c as a diagnostic criteria back in 2005.16 
Therefore, the true incidence of diabetes were likely to be underestimated in all these 
epidemiological studies. In the present study, HbA1c identified an additional 16.5% of 
patients as diabetic who were previously undiagnosed. This was similar to previous study that 
reported a diabetes incidence of 12% in acute myocardial infarction patients who underwent 
glucose tolerance test at 2 months post-discharge.7 Therefore, using HbA1c as a diagnostic 
criteria, the present study demonstrated an overall diabetes incidence of 35.9%. As FPG and 
HbA1c are measuring different physiological processes in acutely unwell patients, their 
concordance in diagnosing diabetes is poor despite a significant correlation. 
Prognostic value of FPG versus glycated hemoglobin 
Previous studies suggest that the pathophysiological relationship between HbA1c and 
FPG in acutely unwell patients may be conceptualized into “cause” and “effect”.3, 18 An 

















cardiovascular risk profile and therefore the cause of the acute myocardial infarction.18 In 
contrast, the effect of a subsequent larger myocardial infarct size is the observed 
epiphenomenon of stress hyperglycemia.3 
Timmer and co-workers demonstrated that stress hyperglycemia was an 
epiphenomenon reflecting more extensive myocardial damage during acute STEMI.18 This is 
due to a relative insulin deficiency during acute stress, and increased stress hormones 
associated with extensive myocardial infarction leading to glycogenolysis and 
hyperglycemia.3 Although, stress hyperglycemia was associated with in-hospital and 30 day 
mortality, it was not predictive of long term mortality after correcting for blood pressure, 
heart rate and angiographic findings.18  
In contrast, an elevated HbA1c is associated with higher baseline cardiovascular risk 
characteristics such as higher incidences of hypertension, hypercholesterolemia and multi-
vessel coronary disease on angiography in patients presenting acute myocardial infarction.18 
It is well recognized that diabetic patients with acute myocardial infarction constitutes a high 
risk population and are more likely to have diffuse interstitial fibrosis in the remote, non-
infarcted myocardium 19, leading to greater impairment of myocardial function and 
predispose patients to development of heart failure after myocardial infarction. Therefore, the 
present study provided further incremental evidence that “long term” poor glycemic control 
with an elevated HbA1c was independently associated with more diastolic dysfunction and 
elevated filling pressures after acute STEMI. 
Glycated hemoglobin and left ventricular dysfunction after STEMI 
Although several previous studies showed conflicting results on the association 
between HbA1c and both short and long term mortality in STEMI patients with or without 
diabetes 3, 18, 20, 21 , only 1 study to date has assessed the association between HbA1c and LV 

















E/A ratio/deceleration time 2 months post-myocardial infarction in previously non-diabetic 
patients.7 The authors failed to show a significant correlation between HbA1c and transmitral 
E/A ratio at rest and during isometric exercise. Although the authors claimed that LV systolic 
and diastolic function were related to HbA1c after acute myocardial infarction, it was based 
on a multivariable analysis with HbA1c entered as the dependent outcome variable, and 
transmitral E/A ratio at rest and isometric exercise, deceleration time, and LVEF entered as 
independent predictive variables.7 In contrast, the present study is first in the literature to 
show HbA1c, not FPG, as an independent predictor for LV diastolic dysfunction and filling 
pressures acutely in STEMI patients. 
 
CONCLUSIONS 
Due to the epiphenomenon of stress hyperglycemia in acute STEMI patients, the 
concordance between HbA1c and FPG criteria for the diagnosis of diabetes in previously 
undiagnosed patients is poor. An elevated HbA1c has prognostic value for worse diastolic 
dysfunction and higher filling pressures after acute STEMI compared to FPG. The value of 
routine HbA1c in guiding therapy and predicting outcomes in STEMI patients is worth 
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Figure 1. Scatterplot for FPG and HbA1c on admission in acute STEMI patients. Circles 
indicate non-diabetic patients on clinical history, and crosses indicate pre-existing diabetic 
patients on clinical history. Of the non-diabetic patients, 18 patients had HbA1c ≥ 6.5% on 
admission. 
 
Figure 2. ROC curve for HbA1c in predicting elevated LV filling pressures (average E/e’ ≥ 
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Table 1. Baseline Clinical, Laboratory and Echocardiographic Characteristics of all Patients, and Between Diabetics by History and Glycated 
Hemoglobin versus Non-Diabetics 
Variable  Total population 
(n = 142)  
Diabetics 
(n = 51)  
Non-Diabetics 
(n = 91)  
p value*  
Clinical      
Age (years)  61.8 ± 12.1 63 ± 12 61 ± 12 0.22 
Male gender (%)  74.6 64.7 80.2 0.041 
Systolic BP (mmHg)  126 ± 22 123 ± 23 127 ± 21 0.22 
Diastolic BP (mmHg)  72 ± 12 70 ± 13 74 ± 11 0.05 
Active smoker (%)  31.0 25.5 34.1 0.29 
Hypertension (%)  48.6 66.7 38.5 0.001 
Laboratory  
    
Hemoglobin (g/dL)  144 ± 18 141 ± 22 146 ± 15 0.15 
GFR (mL/min/1.73m2)  80 ± 26 76 ± 32 81 ± 22 0.34 
Total cholesterol (mmol/L)  4.7 ± 1.1 4.5 ± 1.1 4.8 ± 1.1 0.16 
Triglyceride (mmol/L)  1.7 ± 1.4 2.2 ± 2.1 1.4 ± 0.8 0.019 
Low density lipoprotein (mmol/L)  2.8 ± 1.0 2.6 ± 1.0 3.0 ± 1.0 0.028 
High density lipoprotein (mmol/L)  1.1 ± 0.3 1.0 ± 0.2 1.1 ± 0.3 0.038 
Peak cTnI (median, 25th and 75th percentile) (µg/L) 25.5 (4.3, 83.3) 27.0 (3.6, 73.3) 24.5 (5.4, 90.3) 0.52 
Peak CK-MB (median, 25th and 75th percentile) (U/L)  1810 (831, 3585) 1650 (694, 2800) 1910 (976, 3940) 0.12 
HbA1c (%)  6.6 ± 1.6 8.1 ± 1.9 5.7 ± 0.3 <0.001 
FPG (mmol/L)  7.7 ± 2.8 10.4 ± 3.4 6.4 ± 1.0 <0.001 
Echocardiographic  













LVEDV (mL)  117 ± 41 116 ± 37 118 ± 43 0.78 
LVESV (mL)  69 ± 34 69 ± 33 68 ± 35 0.93 
LVEF (%)  43 ± 12 42 ± 12 44 ± 11 0.49 
LV mass (g) 184 ± 57 184 ± 58 184 ± 57 0.99 
Transmitral E wave (m/s)  0.71 ± 0.18 0.75 ± 0.18 0.69 ± 0.18 0.06 
Transmitral A wave (m/s)  0.68 ± 0.22 0.71 ± 0.22 0.66 ± 0.22 0.15 
Transmitral E/A ratio  1.1 ± 0.5 1.1 ± 0.4 1.1 ± 0.5 0.68 
Transmitral deceleration time (ms)  196 ± 48 188 ± 45 200 ± 49 0.17 
Average e’ (cm/s)  7.1 ± 2.5 6.6 ± 2.1 7.4 ± 2.7 0.057 
Average E/e’ ratio  10.9 ± 4.1 12.5 ± 4.8 10.0 ± 3.3 0.001 
*p value by t-test and Mann Whitney U test for Gaussian and non-Gaussian continuous data, and Chi square test for categorical data. BP = blood 
pressure; cTnI = cardiac troponine I; CK-MB = creatinine kinase-MB isoenzyme; HbA1c = glycated hemoglobin; EDV = end-diastolic volume; 














Table 2. Univariable and Multivariable Linear Regression Models for Left Ventricular Diastolic 
Function (Average e’) and Filling Pressures (Average E/e’) After ST-Elevation Myocardial Infarction 
 Univariable   Multivariable  
   Model 1  Model 2 
Variable  Beta  p value   Beta  p value   Beta  p value  
LV diastolic function by average e’ 
Age  -0.239  0.005   -0.273  0.001   -0.254  0.005  
LVEF  0.272  0.001   0.265  0.001   0.231  0.010  
HbA1c  -0.161  0.059   -0.161  0.045   -  -  
FPG -0.025  0.78   -  -   -0.020  0.82  
LV filling pressure by average E/e’ 
Age  0.256  0.002   2.15 0.001   0.232  0.007  
Gender  -0.297  < 0.001   -0.218  0.008   -0.268  0.003  
LVEF  -0.236  0.005   -0.231  0.003   -0.206  0.015  
HbA1c  0.223  0.008   0.168  0.040   -  -  
FPG 0.162  0.078   -  -   0.086  0.323  
HbA1c = glycated hemoglobin; Beta = standardized beta; FPG = fasting plasma glucose; LV = left 
ventricular; EF = ejection fraction. Model 1 included HbA1c and excluded FPG. Model 2 included 
FPG and excluded HbA1c. 
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